Annual report pursuant to Section 13 and 15(d)

Commitments And Contingencies (Details)

Commitments And Contingencies (Details) $ / shares in Units, shares in Millions										1 Months Ended			3 Months Ended	12 Months Ended		15 Months Ended	16 Months Ended	39 Months Ended	63 Months Ended
	Apr. 01, 2021	Dec. 31, 2019 USD ($)	Dec. 18, 2019 USD ($)	Aug. 08, 2019 USD ($)	Sep. 25, 2018 shares	Sep. 24, 2018 USD ($) therapy milestone shares	Feb. 16, 2018 unit $ / shares	Nov. 17, 2017 USD ($)	Dec. 18, 2015 USD ($) unit	Jul. 31, 2019 USD ($)	Nov. 30, 2017 USD ($) $ / shares	Aug. 31, 2017 USD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2019 USD ($) milestone	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2019 USD ($)	Oct. 31, 2017
Operating Leased Assets [Line Items]
Noncontrolling interest ownership percentage by Noncontrolling Owners																					10.00%
Contingent consideration		$ 0												$ 0		$ 0
Change in fair value														(1,256,211)	$ (110,923)
License obligations		0												0	1,250,000	0
Revenues														6,750,351	7,028,378
Potential future regulatory milestone												$ 20,000,000
Royalty agreement, payment received										$ 2,000,000
Period after public launch to terminate agreement										3 years
Buyout option, percentage of net present value of royalty payments										75.00%
Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
Indemnity receivable													$ (5,200,000)							$ 5,200,000
Karbinal Agreement \| TRIS Pharma
Operating Leased Assets [Line Items]
Minimum quantity required \| unit							70,000
Make whole payment (in dollars per unit) \| $ / shares							$ 30
Zylera \| Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
Price (in dollars per unit) \| $ / shares											$ 58.84
Management and handling fee (in dollars per unit) \| $ / shares											$ 4.03
Management and handling fee annual price increase											10.00%
Zylera \| Ulesfia Supply Agreement \| Lachlan Pharmaceuticals
Operating Leased Assets [Line Items]
Minimum quantity required \| unit									20,000
Long-term purchase commitment									$ 1,200,000
Minimum royalty											$ 3,000,000
Lachlan Pharmaceuticals \| Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
License obligation current													(8,700,000)							8,700,000
Accrued royalties																				$ 400,000
Indemnification of pre-acquisition losses											100.00%
Threshold indemnification of legal costs and possible minimum payments											$ 1,000,000
Indemnification of post-acquisition losses, (as a percent)											50.00%
Payments for legal settlements													2,300,000
Decrease in royalty payable													400,000
Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
Change in fair value														1,300,000
CERC-611
Operating Leased Assets [Line Items]
Potential milestone payment				$ 7,500,000
Potential milestone revenue threshold				750,000,000
Potential milestone payment two				12,500,000
Potential milestone revenue threshold two				1,300,000,000
License obligations		0											$ 1,300,000	0		0
Research and development														1,300,000
License and other revenue
Operating Leased Assets [Line Items]
Revenues												$ 25,000,000		100,000	0
Ichorion
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy						3
Consideration issued (in shares) \| shares					5.8	5.8
Contingent consideration						$ 15,000,000
Number of contingent consideration milestones \| milestone						3
Payment for contingent consideration		0														0
Ichorion \| CERC-801, CERC-802, And CERC-803
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy						3
Ichorion \| CERC-913
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy						1
Milestone One \| Scenario, Forecast \| Ichorion
Operating Leased Assets [Line Items]
Payment for contingent consideration																		$ 6,000,000
Milestone Two \| Scenario, Forecast \| Ichorion
Operating Leased Assets [Line Items]
Payment for contingent consideration																		5,000,000
Milestone Three \| Scenario, Forecast \| Ichorion
Operating Leased Assets [Line Items]
Payment for contingent consideration																		$ 4,000,000	$ 4,000,000
Teva Pharmaceutical Industries Ltd. \| Scenario, Forecast \| Millipred
Operating Leased Assets [Line Items]
Semi-annual payment																	$ 75,000
Automatic renewal period	1 year
Armistice \| CERC-611
Operating Leased Assets [Line Items]
Installment payments				$ 100,000
Revenue from related parties														100,000
TRx
Operating Leased Assets [Line Items]
Potential milestone payment								$ 3,000,000
Contingent consideration		$ 0						1,366,633						$ 0		$ 0
Number of contingent consideration milestones \| milestone														2
TRx \| Milestone One
Operating Leased Assets [Line Items]
Gross profit															12,600,000
Contingent consideration								3,000,000							$ 0
TRx \| Milestone Two
Operating Leased Assets [Line Items]
Contingent consideration								2,000,000
TRx \| Milestone Three
Operating Leased Assets [Line Items]
Contingent consideration								$ 2,000,000
Cost of Sales \| Lachlan Pharmaceuticals \| Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
Gain related to litigation settlement														$ 1,600,000
Former TRx Owners \| Minimum
Operating Leased Assets [Line Items]
Estimate of possible loss			$ 0
Former TRx Owners \| Maximum
Operating Leased Assets [Line Items]
Estimate of possible loss			18,200,000
Contingent consideration \| Former TRx Owners
Operating Leased Assets [Line Items]
Damages sought			3,000,000
Loss From Improper Treatment \| Former TRx Owners
Operating Leased Assets [Line Items]
Damages sought			$ 9,200,000